Pharmaceutical stocks have been on fire this year. The iShares U.S. Pharmaceuticals ETF (NYSEMKT: IHE), which tracks 43 drugmakers, is up almost 29% year to date and 11% over the past month.
There are lots of great stocks in this sector. But one that investors should be watching closely right now is AbbVie (NYSE: ABBV). The company is focused on drugs that treat a range of diseases in the areas of immunology, rheumatology, gastroenterology, dermatology, and oncology, among others.
The company released its quarterly results on Oct. 31, and they exceeded Wall Street’s forecasts. Sales climbed 9.1% to $15.78 billion, which was significantly higher than the $15.59 billion expected. The company posted earnings of $1.86 per share, 11 cents above the $1.77 expected.
AbbVie has a strong stable of top-performing drugs. Sales of Skyrizi, an immunology drug that treats…



